Among other fields, nucleic acid drugs will be jointly developed with Anges MG. With regard to regenerative medicine, the subsidiary Clio at Sendai will take the lead.
Mitsubishi Tanabe news release, December 2, 2015
Mitsubishi Tanabe announces medium-term business plan, + 400 billion Yen within 5 years for 10 product categories